Combined endocrine therapy for breast cancer--new life for an old idea?
Davidson
N E
NE
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002064:Buserelin / Q000627:therapeutic use; D015986:Confounding Factors, Epidemiologic; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000187:drug effects; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D010053:Ovary / Q000187:drug effects; D017697:Premenopause; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D002064:Buserelin